Focusing on modulating the extremes of amino acid metabolism, we use novel engineered human enzymes to reduce amino acid toxicity in the blood. For patients with rare genetic diseases (like Arginase 1 Deficiency) who currently have limited treatment options, we believe in a better future through enzyme therapy.
Patients, families, and healthcare providers play a crucial role in helping us to make our prospective therapies available to those who need them. Learn about current clinical trials in rare genetic diseases, including our pivotal trial in Arginase 1 Deficiency.
Talented, dedicated team members are in good company at Aeglea. We’re looking for individuals who are passionate about using their experience and expertise to help others.
